share_log

Hydreight Announces Nationwide Expansion of Doctor Network to Meet Demand Across All 50 US States

Hydreight Announces Nationwide Expansion of Doctor Network to Meet Demand Across All 50 US States

Hydreight宣佈在全國範圍內擴大醫生網絡,以滿足美國所有50個州的需求
GlobeNewswire ·  2023/08/24 07:30

VANCOUVER, British Columbia and LAS VEGAS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS)(OTCQB: HYDTF)( FSE: SO6), a fast-growing telehealth platform enabling flexible home healthcare, is pleased to announce the ongoing expansion of its doctor network. The Company has successfully increased its network to over 100 physicians spanning across all 50 US states by contracting with an independent network of affiliated medical practices to facilitate the delivery of services to patients. These physician partnerships support screening calls and an increase in consultation requests, as well as new services and offerings that are on the Hydreight platform, where compliance and patient-centred care is of utmost importance.

溫哥華、不列顛哥倫比亞省和拉斯維加斯,2023年8月24日(環球通訊社)海德萊特科技公司(“海德萊特”或“公司”)(TSXV:諾爾斯)(OTCQB:HYDTF)(FSE:SO6),一個支持靈活家庭醫療的快速增長的遠端醫療平臺,很高興地宣佈正在擴大其醫生網路。該公司通過與一個獨立的附屬醫療機構網路簽訂合同,成功地將其網路擴大到覆蓋美國所有50個州的100多名醫生,以促進向患者提供服務。這些醫生合作夥伴關係支持篩查電話和諮詢請求的增加,以及Hydreight平臺上的新服務和產品,其中合規和以患者為中心的護理至關重要。

"Hydreight has become a leader in mobile medical health, providing an unparalleled ecosystem that the Company consistently refines and expands upon to keep up with patient needs and service preferences," said Shane Madden, CEO of Hydreight. "The expansion of our doctor network complements our established network of nurses, business partners and pharmacies. Delivering exceptional patient care is top priority and with over 100 physicians across all 50 US states, we are on our way to achieve our goal of being the nationwide network of mobile medical clinics."

海德瑞特首席執行官謝恩·馬登說:“海德瑞特已經成為移動醫療保健領域的領先者,提供了一個無與倫比的生態系統,公司不斷完善和擴展該生態系統,以跟上患者的需求和服務偏好。”我們醫生網路的擴大是對我們已經建立的護士、商業夥伴和藥房網路的補充。提供卓越的患者護理是重中之重,我們在美國50個州擁有100多名醫生,我們正在實現我們的目標,即成為全國移動醫療診所網路。

Key Highlights:

主要亮點:

  • Doctor network now includes over 100 physicians across all 50 US states
  • Provides increased medical oversight leading to the highest levels of compliance and customer care
  • Supports the platforms overall expansion and increase in booking requests, approximately up 195% since January 2023 in compared to the first 6 months of 2022
  • Enables Hydreight to onboard more white-label clients
  • Hydreight's doctor network will continue to expand as the Company achieves its growth initiatives
  • Extending the telemedicine hours of operation
  • 醫生網路現在包括美國50個州的100多名醫生
  • 提供更多的醫療監督,實現最高級別的合規和客戶關懷
  • 支持平臺的整體擴展和預訂請求的增加,與2022年前6個月相比,自2023年1月以來增長了約195%
  • 使Hydreight能夠加入更多白標客戶端
  • 隨著公司實現其增長計劃,海德萊特的醫生網路將繼續擴大
  • 延長遠端醫療的運營時間

Expanded Doctor Network

擴展的醫生網路

With a commitment to both compliance and creating a seamless and supportive patient/provider experience, the Company will continue to expand its doctor network. The Company has seen approximately a 195% increase in booking requests since January 2023 in comparison to the first 6 months of 2022, commensurate with its expansion and new service offerings. Additionally, through the Company's white-label strategy, the doctor network extends its reach to benefit other franchises and organizations seeking these services.

該公司承諾遵守並創造無縫和支持性的患者/提供者體驗,將繼續擴大其醫生網路。自2023年1月以來,與2022年前6個月相比,該公司的預訂請求增加了約195%,這與其擴張和提供的新服務相稱。此外,通過公司的白標戰略,醫生網路擴大了其覆蓋範圍,使尋求這些服務的其他特許經營權和組織受益。

Hydreight's platform continues to expand towards individualized healthcare offerings and patient specific medications and services such as NAD (Nicotinamide Adenine Dinucleotide) and Semaglutide (among others), which are experiencing heightened demand among the broader public. The Hydreight platform connects patients and providers, seamlessly integrates compliance and medical oversight with the convenience and personalized care and one-on-one interactions.

Hydreight的平臺繼續擴展到個性化的醫療保健產品和針對患者的藥物和服務,如NAD(煙酰胺腺嘌呤二核甘酸)和Semaglutie(以及其他),這些產品在更廣泛的公眾中面臨著更高的需求。Hydreight平臺將患者和提供商連接起來,將合規和醫療監督與便利和個性化護理以及一對一互動無縫地結合在一起。

Nicotinamide Adenine Dinucleotide ("NAD") is a key coenzyme for energy metabolism with diverse benefits, including cognitive enhancement, improved athletic performance, weight management, pain reduction, anti-aging effects, and more.

煙酰胺腺嘌呤二核甘酸(NAD)是一種能量代謝的關鍵輔酵素,具有多種益處,包括增強認知、改善運動能力、控制體重、減輕疼痛、抗衰老等。

Semaglutide, a GLP-1 receptor agonist, aids weight loss and diabetes management by lowering blood glucose, slowing gastric emptying, curbing appetite, and has potential applications in heart health, PCOS, addiction, neurodegenerative diseases, and sleep apnea.

Semagluide是一種GLP-1受體激動劑,通過降低血糖、減緩胃排空、抑制食慾來幫助減肥和糖尿病治療,並在心臟健康、多囊卵巢綜合徵、成癮、神經退行性疾病和睡眠呼吸暫停等方面具有潛在的應用。

About Hydreight Technologies Inc.
Hydreight Technologies Inc. (TSXV: NURS)( OTCQB: HYDTF)( FSE: SO6) is a home healthcare and wellness platform that bridges the gap between providers and patients and empowers nurses, med spa technicians, and other licensed healthcare professionals to deliver services on a flexible schedule or to add mobile services to existing location-based operations. Hydreight facilitates medical director oversight, liability insurance, competitively priced prescriptions via a 503B licensed pharmacy, and more. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, managing patient data, and more, making it possible to deliver mobile medicine across 50 states. Learn more at Hydreight.com.

海德萊特技術公司簡介
Hydreight Technologies Inc.(多倫多證券交易所股票代碼:NOS)(OTCQB:HYDTF)(多倫多證券交易所股票代碼:SO6)是一款家庭保健和健康平臺,可以彌合提供者和患者之間的差距,並使護士、醫療溫泉技術人員和其他有執照的保健專業人員能夠靈活地提供服務,或在現有的基於位置的運營中增加移動服務。海德萊特通過503B特許藥房為醫療董事監管、責任保險、具有競爭力的價格處方提供便利。該平臺包括一套內置的、易於使用的完全集成的工具,用於會計、文檔、銷售、庫存、預訂、管理患者數據等,使其能夠在50個州提供移動醫療。欲瞭解更多資訊,請訪問Hydreight.com。

You can download the Hydreight Wellness App from the Apple App store or Google Play Store , and prospective service providers can sign up at: Hydreight.com/start-a-business/.

您可以從Apple App Store或Google Play Store下載Hydreight Wellness App,潛在的服務提供商可以在以下網址註冊:Hydreight.com/Start-a-Business/。

On behalf of the Board of Directors

我謹代表董事會

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Telephone: (480) 790 6886

肖恩·馬登
董事和首席執行官
海德萊特科技公司
電話:(480)7906886

For further information about Hydreight, please contact:

欲瞭解有關海德萊特公司的更多資訊,請聯繫:

Investor Relations
Contact – Alyssa Barry
Email: ir@hydreight.com
Telephone: 1-833-947-5227

投資者關係
聯繫人--Alyssa Barry
電子郵件:ir@hydreight.com
電話:1-833-947-5227

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

TSXV及其監管服務提供商(該術語在TSXV的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

本新聞稿不構成在美國出售證券的要約。正在發行的證券沒有,也不會根據修訂後的1933年美國證券法註冊,如果沒有美國註冊或美國註冊要求的適用豁免,此類證券不得在美國境內發行或銷售。

Cautionary Note Regarding Forward-Looking Information

關於前瞻性資訊的注意事項

This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect", "approximately" or similar expressions and includes information regarding expectations for the Company's growth in 2023.

本新聞稿包含構成適用證券法定義的“前瞻性資訊”的陳述,包括有關公司對未來業務活動和經營業績的計劃、意圖、信念和當前預期的陳述。前瞻性資訊通常由“可能”、“將”、“可能”、“應該”、“將”、“打算”、“計劃”、“預期”、“相信”、“估計”、“預計”、“大約”或類似的表述來識別,包括有關對公司2023年增長的預期的資訊。

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or predictions concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

請投資者注意,前瞻性資訊不是基於歷史事實,而是反映了公司管理層對未來結果或事件的預期、估計或預測,這些預期、估計或預測是基於在陳述發表之日被認為是合理的管理層的意見、假設和估計。雖然本公司相信該等前瞻性資料所反映的預期是合理的,但該等資料包含風險及不確定因素,不應過分依賴該等資料,因為未知或不可預測的因素可能會對本公司未來的業績、表現或成就產生重大不利影響。可能導致實際結果與前瞻性資訊中預測的結果大相徑庭的關鍵因素包括:就公司經營的業務獲得必要的監管和其他批准的能力和/或公司股票在多倫多證券交易所上市對關係的潛在影響,包括與監管機構、員工、供應商、客戶和競爭對手的關係;一般經濟、商業和政治條件的變化,包括金融市場的變化;適用法律的變化;遵守廣泛的政府監管;以及由於成為上市實體而轉移管理時間。這些前瞻性資訊可能受到公司業務和市場狀況中的風險和不確定因素的影響。

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

如果這些風險或不確定性中的一個或多個成為現實,或者前瞻性資訊背後的假設被證明是不正確的,實際結果可能與本文中描述的預期、計劃、預期、相信、估計或預期的結果大不相同。儘管該公司試圖識別可能導致實際結果大不相同的重要風險、不確定因素和因素,但可能還有其他因素導致結果與預期、估計或預期的不同。除非適用法律另有要求,否則公司不打算也不承擔任何義務更新這些前瞻性資訊。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論